Healthcare Services

Cardiac Amyloidosis Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Cardiac Amyloidosis Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The cardiac amyloidosis market has experienced robust expansion in recent years. This market is expected to increase from $5.73 billion in 2025 to $6.24 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. The strong growth observed historically stems from improved detection of uncommon cardiac conditions, developments in echocardiography and MRI diagnostic tools, a rise in reported cases of amyloidosis, the establishment of more specialist cardiology clinics, and the wider provision of supportive care alternatives.

The cardiac amyloidosis market is set to witness robust expansion in the coming years. It is forecast to climb to $8.71 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.7%. This anticipated growth during the forecast period is fueled by the escalating development of disease-modifying therapies, the increasing embrace of genetic testing, the proliferation of specialized amyloidosis treatment centers, rising investments in rare disease research, and a heightened emphasis on personalized cardiac interventions. Prominent trends expected in the forecast period include a stronger focus on achieving early and precise diagnosis, the growing adoption of advanced cardiac imaging methods, the expanding utilization of biomarker-based screening, the broadening of targeted therapeutic strategies, and improved awareness among cardiologists.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp

What Key Drivers Are Influencing The Growth Of The Cardiac Amyloidosis Market?

The cardiac amyloidosis market is expected to expand due to the growing geriatric population. This demographic refers to older adults, typically aged 65 and above, who often require specialized healthcare and support as a result of aging-related changes. The increase in the geriatric population is attributed to rising life expectancy, advancements in healthcare, and declining birth rates. A larger geriatric population contributes to a higher prevalence of cardiac amyloidosis, given that aging is a significant risk factor for the accumulation of amyloid protein in the heart. For instance, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Therefore, the expanding geriatric population will drive the cardiac amyloidosis market.

What Major Segment Divisions Exist Within The Cardiac Amyloidosis Market?

The cardiac amyloidosis market covered in this report is segmented –

1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis

2) By Treatment: Chemotherapy, Supportive Care, Stem Cell Transplant, Targeted Therapy

3) By End-User: Hospitals, Clinics

Subsegments:

1) By Light Chain Amyloidosis: AL (Immunoglobulin Light Chain) Amyloidosis with Cardiac Involvement, AL Amyloidosis without Cardiac Involvement

2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)

Which Market Trends Are Creating New Opportunities In The Cardiac Amyloidosis Market?

Major companies active in the cardiac amyloidosis market are prioritizing technological advancements, such as artificial intelligence (AI)-based software-only diagnostic tools, to improve early detection and enhance clinical outcomes for individuals with this often-unrecognized disease. An artificial intelligence (AI)-based, software-only medical device designed to identify cardiac amyloidosis serves as a diagnostic instrument that utilizes AI to analyze echocardiographic images and discern disease indicators without necessitating additional hardware or extensive patient data. For instance, in November 2024, Ultromics Ltd., a UK-based health technology firm, secured FDA clearance for EchoGo Amyloidosis, an AI-powered clinical tool developed for the early detection of cardiac amyloidosis. This device is the first within the FDA’s Total Product Lifecycle Advisory Program (TAP) to receive marketing authorization. By employing artificial intelligence, EchoGo Amyloidosis scrutinizes echocardiograms to detect the disease from a single clip, thereby addressing the pressing need for earlier diagnosis before it advances undetected.

Which Companies Are Leading Innovation In The Cardiac Amyloidosis Market?

Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Neurimmune AG, Attralus Inc., Oncopeptides, SOM Biotech, Amylyx Pharmaceuticals, AstraZeneca plc, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb Company, AbbVie Inc., Roche Holding AG, Johnson & Johnson, CSL Limited

Read the full cardiac amyloidosis market report here:

https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Cardiac Amyloidosis Market?

North America was the largest region in the cardiac amyloidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cardiac Amyloidosis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21128&type=smp

Browse Through More Reports Similar to the Global Cardiac Amyloidosis Market 2026, By The Business Research Company

Remote Cardiac Monitoring Global Market Report

https://www.thebusinessresearchcompany.com/report/remote-cardiac-monitoring-global-market-report

Remote Cardiac Monitoring Global Market Report

https://www.thebusinessresearchcompany.com/report/remote-cardiac-monitoring-global-market-report

Cardiovascular Monitoring And Diagnostic Devices And Equipment Global Market Report

https://www.thebusinessresearchcompany.com/report/cardiovascular-monitoring-and-diagnostic-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795